Loading
Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.
Clemens Kratochwil is a nuclear medicine physician at Heidelberg University Hospital, working within the NCT and DKFZ network. His specialisms are targeted alpha therapy, PSMA radioligands and dosimetry in prostate cancer. He reported the first patients treated with actinium-225 PSMA therapy, published in the Journal of Nuclear Medicine as 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. That first clinical experience launched the alpha-emitter era in prostate cancer, and he continues to work on actinium-225 PSMA agents and their dosimetry. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer | Journal of Nuclear Medicine | 2016 |
Shares Journal of Nuclear Medicine, European Association of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ.
Shares Journal of Nuclear Medicine, European Association of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ, PSMA.
Shares Journal of Nuclear Medicine, PSMA, Prostate cancer.
Shares Targeted alpha therapy, PSMA, Prostate cancer.
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.
Shares Targeted alpha therapy, PSMA, Prostate cancer.
Shares Journal of Nuclear Medicine, PSMA.